Perimenopause Annual Evaluation Checklist: What to Review Every Year

Why a Structured Annual Visit Matters in Perimenopause

Perimenopause is not a single event. It is a multi-year hormonal transition driven by declining ovarian follicle reserve, rising FSH, and progressively erratic estradiol secretion. The Stages of Reproductive Aging Workshop (STRAW+10) criteria, published in Fertility and Sterility in 2012, formalized staging into early and late menopause transition based on cycle variability and FSH levels [1].

Without a structured annual visit, symptoms are often normalized rather than treated. A 2021 survey published in Menopause found that fewer than 25% of women in perimenopause reported receiving a comprehensive risk discussion from their clinician during this window [2].

What Changes Each Year

Estradiol does not decline in a straight line. It fluctuates widely in early perimenopause, sometimes spiking above premenopausal norms, before trending downward in late transition. This means a lab result from two years ago may not reflect current physiology. Annual reassessment of both symptoms and selected labs keeps the clinical picture current.

The Cost of Delayed Assessment

Bone loss accelerates markedly in late perimenopause. The Study of Women's Health Across the Nation (SWAN) documented lumbar spine bone mineral density losses averaging 1.8% per year in the two years surrounding the final menstrual period, roughly three times the premenopausal rate [3]. Identifying risk early allows timely intervention before fracture risk becomes clinically significant.

Step 1: Symptom Inventory and Quality-of-Life Scoring

The first task at any annual visit is a standardized symptom review. Self-report scales outperform open-ended questioning because women often minimize symptoms they assume are "just aging."

Validated Instruments to Use

The Menopause Rating Scale (MRS) and the Greene Climacteric Scale both provide domain-specific scores across somatic, psychological, and urogenital symptoms. The MRS assigns numerical severity scores across 11 items; a total score above 16 is considered moderate-to-severe burden. Using the same scale year-over-year gives a quantitative trend line, not just a subjective impression.

Vasomotor symptoms (hot flashes, night sweats) affect approximately 80% of perimenopausal women, and moderate-to-severe symptoms affect around 25-30% [4]. Document frequency (episodes per 24 hours) and severity (mild, moderate, severe) at every visit.

Sleep and Cognitive Symptoms

Sleep disruption is often secondary to nocturnal vasomotor events rather than a primary sleep disorder. The Insomnia Severity Index (ISI) score should be recorded. Cognitive complaints, particularly word-finding difficulties and short-term memory lapses, occur in roughly 60% of perimenopausal women according to a SWAN substudy [5]. A baseline cognitive screen using the MoCA is reasonable when complaints are significant.

Step 2: Hormonal Laboratory Panel

Hormone testing in perimenopause is more useful for staging and monitoring treatment than for diagnosis. The NAMS 2023 Position Statement notes that FSH and estradiol values alone cannot confirm or exclude perimenopause in a woman with a uterus who is still cycling, but serial values help track progression [6].

Core Labs at Each Annual Visit

| Lab | Reference Range Context | Clinical Use | |---|---|---| | FSH | >25 IU/L (day 2-5) supports late transition | Staging; monitoring HRT adequacy | | Estradiol (E2) | Variable; low E2 with high FSH confirms late transition | Dose titration on therapy | | TSH | 0.4-4.0 mIU/L | Rule out thyroid dysfunction mimicking perimenopause | | CBC | Standard reference ranges | Screen for anemia with heavy irregular bleeding | | Fasting glucose / HbA1c | Glucose <100 mg/dL; HbA1c <5.7% | Metabolic risk surveillance |

Thyroid dysfunction is particularly important to exclude. Hypothyroidism presents with fatigue, mood changes, and menstrual irregularity, all symptoms that overlap substantially with perimenopause. The American Thyroid Association recommends TSH screening in women over 35 every five years, with more frequent testing if symptoms are present [7].

When to Add AMH

Anti-Müllerian hormone (AMH) reflects ovarian reserve. In women with ambiguous staging or in those considering fertility preservation, AMH below 0.5 ng/mL in combination with clinical history supports late reproductive stage or early perimenopause. AMH is not routinely required at every annual visit but has a role in select cases.

Step 3: Cardiovascular Risk Stratification

The cardiovascular risk profile shifts during perimenopause. Estrogen loss is associated with less favorable LDL:HDL ratios, rising triglycerides, increased central adiposity, and endothelial dysfunction. The American Heart Association's 2020 Scientific Statement on menopause and cardiovascular disease highlighted that the perimenopausal transition itself is an independent risk period, separate from post-menopausal status [8].

Annual Lipid Panel and Blood Pressure

A full fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) should be obtained at least every two years, or annually if prior values were borderline or if HRT has been initiated or changed. Estrogen therapy can lower LDL by 10-15% but may raise triglycerides, particularly with oral formulations [9]. This is clinically relevant: transdermal estradiol bypasses first-pass hepatic metabolism and has a more neutral effect on triglycerides than oral estrogen.

Blood pressure should be measured at every visit. Hypertension prevalence rises sharply across the perimenopausal years. The 2017 ACC/AHA hypertension guideline defines Stage 1 hypertension as systolic 130-139 mmHg or diastolic 80-89 mmHg, thresholds that many perimenopausal women cross without knowing it [10].

10-Year ASCVD Risk Calculation

The Pooled Cohort Equations calculator (available at tools.acc.org) should be run at every annual visit for women 40 and older. An ASCVD risk score at or above 7.5% warrants statin discussion, and this threshold is reached by many perimenopausal women in their late 40s, particularly those with dyslipidemia, hypertension, or a smoking history.

Step 4: Bone Health Assessment

Bone loss during perimenopause is silent. Most women do not know their trabecular bone is demineralizing until a DXA scan or, worse, a fracture makes it obvious.

When to Order DXA

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) recommends DXA for all women at age 65, but an earlier scan is indicated in perimenopausal women with one or more risk factors: family history of hip fracture, current smoking, BMI <18.5, long-term glucocorticoid use, or a personal history of fragility fracture [11]. The FRAX calculator (shef.ac.uk/FRAX) quantifies 10-year fracture probability and should be completed at each visit for any woman with identified bone risk factors.

Calcium and Vitamin D Status

Serum 25-hydroxyvitamin D should be checked at baseline and periodically thereafter. The Endocrine Society defines vitamin D sufficiency as 25-OH-D above 30 ng/mL (75 nmol/L) [12]. Dietary calcium intake should be reviewed: the National Institutes of Health recommends 1,000 mg daily for women aged 19-50, increasing to 1,200 mg after age 50. Supplementation should close the gap between dietary intake and target, not exceed it.

Bisphosphonate Consideration

For women with T-score at or below -2.5, or T-score between -1.0 and -2.5 with a FRAX 10-year hip fracture probability at or above 3%, pharmacologic therapy should be discussed. Alendronate 70 mg weekly remains the most widely studied first-line agent, with the Fracture Intervention Trial (FIT) showing a 47% reduction in hip fracture over three years versus placebo [13].

Step 5: Cancer Screening Alignment

Annual visits are an opportunity to confirm all age-appropriate cancer screenings are current.

Breast Cancer

The USPSTF 2024 updated recommendation advises biennial screening mammography for all women starting at age 40 [14]. For women with dense breast tissue, supplemental ultrasound or MRI screening may be discussed. BRCA carrier status or a first-degree relative with breast cancer may warrant annual MRI starting at 30 or earlier.

Cervical Cancer

Cervical cancer screening using Pap smear plus HPV co-testing every five years is recommended from age 30 to 65 [15]. Women who have had a hysterectomy with removal of the cervix for benign indications do not need continued cervical screening.

Colorectal Cancer

The USPSTF recommends colorectal cancer screening starting at age 45 for average-risk adults [16]. Options include colonoscopy every ten years, annual fecal immunochemical test (FIT), or stool DNA test every one to three years. The annual visit is the right time to confirm which method is in use and when it is due.

Endometrial Health

Unscheduled uterine bleeding in perimenopause is common but requires investigation. Any bleeding more than 12 months after the last menstrual period, or persistently heavy or intermenstrual bleeding before that point, warrants endometrial biopsy and pelvic ultrasound to exclude endometrial hyperplasia or carcinoma. This is not a screening test for asymptomatic women; it is an urgent evaluation triggered by abnormal bleeding.

Step 6: Mental Health and Cognitive Screening

The perimenopausal transition confers a two- to four-fold increase in risk of a first-episode major depressive disorder, independent of prior psychiatric history. This figure comes from the Harvard Study of Moods and Cycles, which followed women prospectively through the transition [17].

PHQ-9 at Every Annual Visit

The USPSTF recommends depression screening for all adults using a validated tool such as the PHQ-9 [18]. A score of 10 or above suggests moderate depression requiring clinical action. Perimenopausal women who score in this range should be assessed for whether symptoms are primarily vasomotor-driven (treating hot flashes may resolve secondary mood disruption) or represent a primary depressive episode requiring antidepressant therapy or psychotherapy.

Anxiety Screening

The GAD-7 screens for generalized anxiety disorder in seven items. Anxiety disorders are underdiagnosed in this age group. A GAD-7 score of 10 or above warrants clinical discussion and, if indicated, referral.

The Two-Question Rapid Screen

When time is limited, the PHQ-2 ("Over the past two weeks, have you felt down, depressed, or hopeless?" and "Have you felt little interest or pleasure in doing things?") takes under one minute and has sensitivity of 97% for detecting major depression in primary care settings, per the original validation study in Archives of Internal Medicine [19]. A positive PHQ-2 prompts full PHQ-9 completion.

Step 7: Treatment Review and Adjustment

For women already on hormone therapy, the annual visit is the time to reassess the benefit-risk balance and adjust dosing.

Reviewing HRT Dose and Route

The NAMS 2023 Position Statement affirms that hormone therapy remains the most effective treatment for vasomotor symptoms, with estrogen preparations showing 75-90% reduction in hot flash frequency versus 25-50% for placebo [6]. Treatment decisions should be individualized. The minimum effective dose should be used, but "minimum" is patient-specific: a woman still having 12 hot flashes per day on 0.025 mg/day transdermal estradiol patch may need uptitration to 0.05 mg/day.

Progestogen type matters for women with a uterus. Micronized progesterone 200 mg nightly for 12 days per cycle (or 100 mg nightly continuously) is associated with a more favorable breast cancer risk profile compared to synthetic progestins, based on the E3N cohort study (N=54,548) [20].

Non-Hormonal Options for Vasomotor Symptoms

For women who cannot or prefer not to use hormone therapy, evidence-based non-hormonal options include:

• Fezolinetant (Veozah) 45 mg daily: FDA-approved May 2023, a neurokinin 3 receptor antagonist that reduced moderate-to-severe hot flash frequency by 60% at 12 weeks versus 34% for placebo in the SKYLIGHT 1 trial [21].
• Paroxetine mesylate (Brisdelle) 7.5 mg nightly: the only FDA-approved SSRI specifically for vasomotor symptoms, with a modest but consistent effect (approximately 33-67% reduction in hot flash frequency) [22].
• Venlafaxine 75 mg daily: off-label but supported by multiple randomized trials, showing roughly 60% reduction in hot flash composite score [23].
• Gabapentin 300 mg three times daily: off-label, with a Cochrane review finding moderate benefit, though sedation limits tolerability for many women [24].

Low-Dose Oral Contraceptives in Perimenopause

Combined oral contraceptives (COCs) at low ethinyl estradiol doses (10-20 mcg) provide cycle regulation, contraception, and vasomotor control. ACOG Practice Bulletin 110 supports their use in non-smoking, normotensive perimenopausal women without additional thrombotic risk factors [25]. COCs mask the natural FSH rise, so they should be discontinued at age 50-51 with a hormone check to assess menopausal status.

Step 8: Genitourinary Health

Genitourinary syndrome of menopause (GSM) encompasses vaginal dryness, dyspareunia, urinary urgency, and recurrent urinary tract infections secondary to estrogen deficiency in urogenital tissues. GSM affects up to 45% of postmenopausal women, and symptoms begin during perimenopause, before the final menstrual period, in a meaningful proportion [26].

Assessment at Each Visit

Ask directly. GSM is chronically underreported because patients are embarrassed. A single question, "Have you noticed vaginal dryness, discomfort with intercourse, or new urinary urgency?" captures the majority of cases.

Topical vaginal estrogen (0.01% estradiol cream, estradiol vaginal ring releasing 7.5 mcg/day, or estradiol vaginal tablet 10 mcg) is effective, has minimal systemic absorption, and does not require a progestogen in women with a uterus when used at approved low doses [6]. Ospemifene 60 mg orally daily is an FDA-approved oral SERM option for women who prefer not to use vaginal preparations.

Step 9: Metabolic and Weight Assessment

Perimenopausal women gain an average of 1.5 kg per year during the transition, much of it redistributed centrally rather than peripherally. This is not simply caloric; it reflects the shift in adipose tissue distribution driven by declining estrogen [27].

Waist Circumference and BMI

Waist circumference above 88 cm (35 inches) in women is a metabolic syndrome criterion. Measure it annually. BMI <25 kg/m² is the general target, but waist circumference adds information that BMI alone misses.

Fasting glucose and HbA1c annual monitoring is appropriate given that the risk of type 2 diabetes increases across the perimenopausal window. The ADA 2024 Standards of Care recommend screening every three years for adults with no risk factors, and annually for those with prediabetes (HbA1c 5.7-6.4%) or other risk factors [28].

Annual Evaluation Summary Table

| Checklist Item | Frequency | Responsible Action | |---|---|---| | Symptom inventory (MRS or Greene scale) | Every visit | Clinician + patient | | FSH, estradiol, TSH | Annually or per clinical need | Lab order | | Fasting lipid panel | Every 1-2 years | Lab order | | Blood pressure | Every visit | Clinical measurement | | ASCVD 10-year risk score | Annually after age 40 | Pooled Cohort Equations | | PHQ-9 depression screen | Annually | Standardized form | | GAD-7 anxiety screen | Annually | Standardized form | | DXA (if indicated) | Baseline; repeat per T-score | Imaging referral | | 25-OH Vitamin D | Baseline; annually if deficient | Lab order | | Mammogram | Every 1-2 years from age 40 | Imaging referral | | Pap + HPV co-test | Every 5 years (ages 30-65) | Gynecology or primary care | | Colorectal screening | Per chosen modality schedule | Referral or lab | | GSM assessment | Every visit (direct question) | Clinical discussion | | Waist circumference + BMI | Every visit | Clinical measurement | | HRT dose-route-type review | Every visit | Treatment adjustment |